KFDA to extend study period of IPA

Published: 2011-02-07 06:59:00

Updated: 2011-02-07 06:59:00

The Korea Food and Drug Administration hinted that it will allow more time for manufacturers of painkillers containing isopropylantipyrine (IPA) to prove its safety profile.
On January 12, the drug agency ordered the manufacturers to elucidate the possible link between IPA therapy and adverse ev...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK